Framework nucleic acid aptamer targeting SARS-COV-2 spike protein and application

By designing a framework nucleic acid aptamer targeting SARS-CoV-2 spike protein, the tetrahedral structure is assembled using the principle of base complementary pairing, and specifically identifying and combining the spike protein of the new coronavirus, the novel coronavirus in the existing technology is solved The efficiency and safety of infection treatment have achieved efficient and lasting anti-infection effects and are suitable for mutant viruses.

CN118956881APending Publication Date: 2024-11-15EIGHTH AFFILIATED HOSPITAL SUN YAT SEN UNIV (SHENZHEN FUTIAN)
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411065092.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art has the challenge of long research and development cycle, limited efficacy, obvious side effects, and difficult to cope with the mutant strain in the treatment or prevention of SARS-CoV-2, and the production of neutralizing antibodies is limited, which cannot provide high efficiency, durability and application. Drugs for mutant viruses.

Method used

Design framework nucleic acid aptamers targeting SARS-CoV-2 spike proteins, assemble and form tetrahedral framework nucleic acid aptamers through the principle of base complementary pairing, specifically identify and bind the new coronavirus spike protein to prevent it from being connected to the cell surface. ACE2 receptor binds to achieve anti-infection effect.

Benefits of technology

It has achieved efficient anti-infection against the new coronavirus SARS-CoV-2, with a longer anti-infection time. It is suitable for mutated viruses. It has simple synthesis, high safety, low immunogenicity, short R&D cycle, and can enhance local drug delivery. concentration, reduce dosage and toxic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to a framework nucleic acid aptamer targeting SARS-COV-2 spike protein and application of the framework nucleic acid aptamer. According to the invention, three specific aptamer sequences aiming at different mutation regions of RBD of spike protein on the surface of a new coronavirus and a structure sequence of a framework tetrahedron (tFNA) are designed, the specific aptamer sequences are connected to a tetrahedron nucleic acid framework by utilizing a base complementary pairing principle, and a framework nucleic acid aptamer (A-tFNA) nano structure is synthesized; according to the framework nucleic acid aptamer, targeted capture of the novel coronavirus SARS-CoV-2 spike protein is effectively achieved, so that the situation that the novel coronavirus SARS-CoV-2 spike protein is combined with an ACE2 receptor on the cell surface to infect cells is prevented, the anti-infection effect on the novel coronavirus SARS-CoV-2 can be effectively achieved, and the anti-infection time is longer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a framework nucleic acid aptamer targeting SARS-COV-2 spike protein and its application. Background Art

[0002] The drugs for treating or preventing the novel coronavirus infection SARS-CoV-2 mainly include vaccines, small molecule drugs, macromolecule drugs, neutralizing antibodies, and nano drugs. Among them, the vaccine development cycle is long, and the relevant vaccines for the current epidemic strains cannot be promoted in a timely manner, and the vaccination cannot play an efficient protective role for a long time. Most small molecule drugs are old drugs with new uses, lack of specificity, limited efficacy, and obvious side effects. The development of neutralizing antibodies cannot be mass-produced due to the limited source of plasma, and it is difficult to cope with the challenges of the constantly mutating new coronavirus strains. Therefore, it is urgent to develop a new drug with higher anti-infection efficiency, longer anti-infection time, and can be applied to mutated viruses.

[0003] Aptamers are short single-stranded oligonucleotides that are screened from synthetic DNA / RNA libraries and can bind to various targets with high affinity and specificity, so they are also called "molecular antibodies". Aptamers with high affinity to target substances can be screened from random single-stranded nucleic acid sequence libraries using the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technology. Aptamers have the characteristics of easy chemical modification, strong binding specificity, good biocompatibility and short R&D cycle.

[0004] Compared with vaccines, macromolecular drugs, and small molecule drugs, nanomedicines have high levels of safety, biodegradability, simple synthesis, and easy functional modification. Existing nanomaterials include inorganic nanomaterials, metal nanoparticles, organic polymer nanoparticles, etc. Compared with inorganic and traditional organic nanomaterials, nucleic acid nanomaterials can synthesize DNA nanostructures with uniform morphology, easy chemical modification, and high biocompatibility through the principle of base complementary pairing. Compared with existing technologies, neutralizing aptamers are simple to synthesize, have stronger binding specificity, low immunogenicity, and a shorter R&D cycle. They can enhance local drug concentrations, reduce drug dosages and toxic side effects. More importantly, Aptamer is naturally a nucleic acid sequence that can be precisely and controllably combined with DNA nanostructures without any modification or chemical reaction, making the synthesis process more convenient and quick, and the drug concentration stable and consistent. It provides a new idea and solution for the current prevention and control of the infection and spread of the new coronavirus. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a framework nucleic acid aptamer targeting the SARS-COV-2 spike protein and its application.

[0006] In order to achieve the above-mentioned invention object, the technical solution adopted by the present invention is:

[0007] In a first aspect, the present invention provides a framework nucleic acid aptamer, wherein the framework nucleic acid aptamer comprises a framework sequence, a linker sequence and an aptamer sequence; the aptamer sequence is connected to the framework sequence through the linker sequence, and then assembled to form a tetrahedral framework nucleic acid aptamer according to the principle of base complementary pairing; the framework sequence comprises four DNA chains, and the nucleotide sequences of the four DNA chains are shown in at least one group of (1)-(3):

[0008] (1)ssDNA A13: 5'-ACACTACGTCAGAACAGCTTGCATCACTGGTCACC AGAGTA-3',

[0009] ssDNA B13: 5'-ACGAGCGAGTTGATGTGATGCAAGCTGAATGCGAGGGT CCT-3',

[0010] ssDNA C13: 5'-TCAACTCGCTCGTAACTACACTGTGCAATACTCTGGTG ACC-3',

[0011] ssDNA D13: 5'-TCTGACGTAGTGTATGCACAGTGTAGTAAGGACCCTCG CAT-3';

[0012] (2)ssDNA A17: 5'-ACATTCCTAAGTCTGAAACATTACAGCTTGCTACACGAGAAGAGCCGCCATAGTA-3',

[0013] ssDNA B17: 5'-TATCACCAGGCAGTTGACAGTGTAGCAAGCTGTAATAGATGCGAGGGTCCAATAC-3',

[0014] ssDNA C17: 5'-TCAACTGCCTGGTGATAAAACGACACTACGTGGGAATCTACTATGGCGGCTCTTC-3',

[0015] ssDNA D17: 5'-TTCAGACTTAGGAATGTGCTTCCCACGTAGTGTCGTTTGTATTGGACCCTCGCAT-3';

[0016] (3)ssDNA A21: 5'-ATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA-3',

[0017] ssDNA B21: 5'-ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG-3',

[0018] ssDNA C21: 5'-ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC-3',

[0019] ssDNA D21: 5'-ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG-3';

[0020] The nucleotide sequence of the aptamer sequence is shown in at least one of (S1)-(S3):

[0021] (S1)5'-CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGC GTTAATGGACA-3';

[0022] (S2)5'-ATCCAGAGTGACGCAGCATTTCATCGGGTCCAAAAGGGGCTGCTCGGGATTGCGGATATGGACACGT-3';

[0023] (S3)5'-CGCAGCACCCAAGAACAAGGACTGCTTAGGATTGCGA TAGGTTCGG-3'.

[0024] Preferably, the aptamer sequence targets the RBD domain of the SARS-CoV-2 spike protein.

[0025] The present invention designs three specific aptamer (Aptamer) sequences for different mutation regions of the RBD of the surface spike protein of the new coronavirus and the structural sequence of the framework tetrahedron (tFNA), and uses the base complementary pairing principle to connect the specific aptamer sequence to the framework nucleic acid tetrahedron to synthesize the framework nucleic acid aptamer (A-tFNA) nanostructure. The framework nucleic acid aptamer effectively achieves the targeted capture of the spike protein of the new coronavirus SARS-CoV-2, thereby preventing it from binding to the ACE2 receptor on the cell surface to infect cells, thereby achieving the anti-infection effect of the new coronavirus SARS-CoV-2.

[0026] Moreover, when exploring whether the spatial distance regulation of aptamers in the formed framework nucleic acid aptamer nanomaterial has a better effect on neutralizing the infection of the new coronavirus, the present invention found that the tetrahedral nucleic acid framework (tFNA) formed by the framework sequences of the three groups of different DNA sequence lengths provided above can accurately control the aptamers connected to the ends of the structure, so that it can more stably bind to the spike protein of the new coronavirus SARS-CoV-2, making the anti-viral infection efficiency higher and the anti-infection time longer.

[0027] Preferably, the nucleotide sequences of the four DNA chains of the framework sequence are as follows:

[0028] ssDNA A17: 5'-ACATTCCTAAGTCTGAAACATTACAGCTTGCTACACGAGAAGAGCCGCCATAGTA-3',

[0029] ssDNA B17: 5'-TATCACCAGGCAGTTGACAGTGTAGCAAGCTGTAATAGATGCGAGGGTCCAATAC-3',

[0030] ssDNA C17: 5'-TCAACTGCCTGGTGATAAAACGACACTACGTGGGAATCTACTATGGCGGCTCTTC-3',

[0031] ssDNA D17: 5'-TTCAGACTTAGGAATGTGCTTCCCACGTAGTGTCGTTTGTATTGGACCCTCGCAT-3'.

[0032] Experimental research found that when the above four DNA chains are used as the framework sequence to synthesize the tetrahedral nucleic acid framework (tFNA), the prepared framework nucleic acid aptamer nanomaterial (A-tFNA) has the best anti-infection effect against the new coronavirus SARS-CoV-2, and its stability is enhanced.

[0033] Preferably, the nucleotide sequence of the aptamer sequence includes three nucleotide sequences shown in (S1)-(S3):

[0034] (S1)5'-CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGC GTTAATGGACA-3';

[0035] (S2)5'-ATCCAGAGTGACGCAGCATTTCATCGGGTCCAAAAGGGGCTGCTCGGGATTGCGGATATGGACACGT-3';

[0036] (S3)5'-CGCAGCACCCAAGAACAAGGACTGCTTAGGATTGCGA TAGGTTCGG-3'.

[0037] The above three aptamers provided by the present invention can specifically recognize different mutation regions of the RBD of the spike protein on the surface of the new coronavirus. When the three are jointly connected and modified on the tetrahedral nucleic acid framework, the prepared framework nucleic acid aptamer nanomaterial can more accurately recognize and bind to the RBD region, thereby effectively preventing it from binding to the ACE2 receptor on the cell surface to infect cells, achieving excellent antiviral infection effects, and are also suitable for mutated new coronaviruses, achieving long-term and efficient prevention and treatment effects.

[0038] Preferably, the nucleotide sequence of the linking sequence comprises tttttttttt.

[0039] Preferably, the effective concentration of the framework nucleic acid aptamer is 200-1000 nM.

[0040] More preferably, the effective concentration of the framework nucleic acid aptamer is 200 nM.

[0041] Through experimental investigation, it was found that the concentration of the framework nucleic acid aptamer was effective when it was 200-1000nM. In order to ensure economy, 200nM was enough to play a corresponding role.

[0042] In a second aspect, the present invention provides a method for preparing the framework nucleic acid aptamer, comprising the following steps:

[0043] The aptamer sequence is connected to the structural end of the framework sequence DNA chain through the linker sequence, and then the four DNA chains of the framework sequence are mixed with 10×TM buffer and water, and then a PCR reaction is performed to obtain the framework nucleic acid aptamer;

[0044] The four DNA chains of the framework sequence have the same volume usage; the usage ratio of the framework sequence, 10×TM buffer and water is 4 μmoL:10 μL:50 μL.

[0045] Preferably, the TM buffer comprises the following components: 200 mmol / L Tris-HCl and 500 mmol / LMgCl2 at pH 8.0.

[0046] Preferably, the conditions of the PCR reaction are: preheating at 95°C for 3 min, denaturation at 95°C for 10 min, and annealing to 4°C for 20 min.

[0047] In a third aspect, the present invention provides the use of the framework nucleic acid aptamer in the preparation of a drug for preventing or treating pneumonia caused by SARS-COV-2 virus infection.

[0048] Compared with the prior art, the present invention has the following beneficial effects:

[0049] (1) The present invention designs three specific aptamer sequences for different mutation regions of the RBD of the spike protein on the surface of the new coronavirus and the structural sequence of the framework tetrahedron (tFNA), and uses the principle of base complementary pairing to connect the specific aptamer sequence to the tetrahedron nucleic acid framework to synthesize the framework nucleic acid aptamer (A-tFNA) nanostructure. The framework nucleic acid aptamer effectively achieves targeted capture of the spike protein of the new coronavirus SARS-CoV-2, thereby preventing it from binding to the ACE2 receptor on the cell surface to infect cells, thereby effectively achieving the anti-infection effect of the new coronavirus SARS-CoV-2, and the anti-infection time is longer;

[0050] (2) The framework nucleic acid aptamer described in the present invention is simple to synthesize, has stronger binding specificity, low immunogenicity, a shorter research and development cycle, and no difference in preparation batches, which has important reference value for preventing and controlling the infection and spread of the new coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 Figure 1 is a synthetic characterization diagram of the framework nucleic acid aptamer, in which: Figure 1 A is the polyacrylamide gel electrophoresis diagram of the sample. Figure 1 B is the transmission electron micrograph of A-tFNA, Figure 1 C is the dynamic light scattering graph of the sample.

[0052] Figure 2 This is a diagram showing the anti-SARS-COV-2 infection effect of the framework nucleic acid aptamer, in which: Figure 2 A is a graph showing the infection of 293T-ACE2 cells by pseudo-SARS-COV-2 transfected with GFP protein. Figure 2 B is a graph showing the fluorescence intensity signal of 293T-ACE2 cells. DETAILED DESCRIPTION

[0053] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following embodiments.

[0054] Unless otherwise specified, the reagents used in the examples are conventional reagents in the art and can be purchased through commercial channels. The experimental operations not specifically described in the examples are conventional operations in the art or can be understood or known by those skilled in the art based on the existing technology or common knowledge they master.

[0055] The anti-infection method of the present invention utilizes the principle of specific recognition of the SARS-CoV-2 S protein nucleic acid aptamer of the new coronavirus (preferentially using the SARS-CoV-2 S protein nucleic acid aptamer adapted to the subtype of Omicron B1.1.529, but not limited to the Omicron subtype, and can also be used for S proteins of other subtypes of SARS-CoV-2). After the nucleic acid aptamer binds to the SARS-CoV-2 spike protein of the new coronavirus, the spike protein is prevented from binding to the ACE2 receptor on the cell surface.

[0056] Example 1. Ordered arrangement design and structural synthesis of framework nucleic acid aptamers (A-tFNA)

[0057] The present invention connects three specific aptamers (S1-S3) designed for different mutation regions of the RBD of the surface spike protein of the new coronavirus to the 5' end of the framework sequence through a linker sequence (nucleotide sequence is tttttttttt), and then assembles them into a tetrahedral framework nucleic acid aptamer through the principle of base complementary pairing. The sequence of the synthetic framework nucleic acid aptamer is shown in Table 2, wherein A-t26 is a tetrahedral framework nucleic acid aptamer prepared by modifying framework nucleic acids of other different base lengths with the aptamers (S1-S3).

[0058] Table 1

[0059]

[0060]

[0061] Table 2

[0062]

[0063] The preparation method of the framework nucleic acid aptamer comprises the following steps:

[0064] The three specific aptamer sequences were connected to the 5' structural ends of the three DNA chains of the framework sequence through the linker sequence, and then 10 μL of each of the four DNA scaffold chains (100 μM) was mixed with 10 μL of 10×TM buffer and 50 μL of Milli-Q water and placed in a PCR instrument for PCR reaction (the final concentration of the framework aptamer was 10 μM). The PCR instrument was set to the following conditions: preheating at 95°C for 3 minutes, denaturing at 95°C for 10 minutes, annealing to 4°C for 20 minutes, and obtaining the framework nucleic acid aptamer; the 10×TM buffer included the following components: 200 mmol / L Tris-HCl at pH 8.0 and 500 mmol / L MgCl2.

[0065] The present invention obtains four groups of framework sequences (t13, t17, t21, t26) by adjusting the base length of the tFNA scaffold chain, and after the three aptamers are connected to different framework nucleic acid DNA chains respectively, the aptamer combinations (A-t13, A-t17, A-t21, A-t26) showing different spatial arrangement distances are obtained through the above preparation method. In order to facilitate confocal microscopy and flow cytometric analysis, the present invention also modifies the 5' end of the A-tFNA top scaffold chain with a cy5 fluorescent group.

[0066] The present invention conducts synthesis characterization analysis on the three prepared framework nucleic acid aptamers (A-t13, A-t17, and A-t21). Figure 1 As shown in A, A-t13, A-t17, A-t21, tFNA without modified Aptamer, and three aptamer cocktail compositions (S1-S3) were subjected to polyacrylamide gel electrophoresis, and the results showed that the three aptamers were connected to tFNA, and the framework nucleic acid aptamer (A-tFNA) was successfully synthesized. And dynamic light scattering (DLS) determined that the sizes of the three synthesized A-tFNAs were larger than those of tFNA ( Figure 1 C), this size difference also indicates the successful synthesis of A-tFNA; for further verification, the present invention uses transmission electron microscopy (TEM) to visualize the morphology of A-tFNA and determines that the particle size of the prepared A-tFNA reaches the nanoscale and the morphology is uniform, which is a prerequisite for being used as a nanomedicine for effective drug delivery in vivo to prevent and treat viral infection ( Figure 2 B).

[0067] Example 2. Effect of A-tFNA on blocking the binding of viral antigens to ACE2 receptors

[0068] (1) Ordered arrangement of aptamer combinations and their synergistic binding to S protein

[0069] The present invention explores the synergistic binding effect of the ordered arrangement of aptamer combinations on S protein, using recombinant SRBD Protein (purchased from MCE) was used as the target, and three different groups of A-tFNA (A-t13, A-t17, and A-t21) were set as the experimental group, and the Aptamer cocktail combination was set as the control group. They were mixed into S RBD The Octet-R biomolecular interaction analysis system was used to analyze the interaction between the neutralizing aptamer and S RBD The binding dissociation constant of the protein was measured to quantitatively obtain the difference in the binding efficiency of the neutralizing aptamer to the S protein between the treatment groups. It was found that the three synthesized A-tFNAs had smaller Kd values ​​than the Aptamer cocktail combination (Apt-Mix), indicating that the present invention successfully prepared a stable framework nucleic acid aptamer nanomaterial by accurately adjusting the length of the framework sequence. Compared with the free aptamer, the framework nucleic acid aptamer of the present invention has a stronger affinity with S RBD The protein has better and more stable affinity, which effectively prevents it from binding to the ACE2 receptor on the cell surface to infect cells, significantly improving the effect of resisting new coronavirus infection.

[0070] (2) Evaluation of the effect of ordered arrangement of neutralizing aptamer combinations on inhibiting viral infection

[0071] The present invention uses 293T-ACE2 cells that highly express ACE receptors as an in vitro research model, and sets four different groups of A-tFNA (A-t13, A-t17, A-t21, A-t26) prepared in Example 1 as experimental groups, and uses an untreated group (ACE2 group), a standard neutralizing antibody group (Antibody group), a random sequence group (nucleotide sequence is 5'-CTACGGACCTAGCATATAACACTAGATTACCTTTGAGAGT TCATCTGCGAACCGA-3') (Random group), an aptamer cocktail combination (Apt-Mix group) and tFNA (tFNA group) without modified Aptamer as control groups. Fake SARS-COV-2 transfected with GFP protein and the above-mentioned experimental control groups are added to 293T-ACE2 cells at the same time for incubation and culture for 1 hour, and then the virus cell culture supernatant is removed, and the cells are washed with PBS to remove excess viruses and neutralizing aptamers. Subsequently, the infection rate of the cells and the cell state are detected. The specific method is as follows.

[0072] 1. Cell proliferation detection: Cell Counting Kit-8 (CCK-8) kit was used for rapid detection of cell proliferation and cytotoxicity.

[0073] 2. Cell infection rate detection: ACE2-293T cells were inoculated in a 12-well plate, and approximately 1×10 4ACE2-293T cells were then added to the cells at a final titer of approximately 1×10 5 TCID 50 / ml of pseudo SARS-COV-2 transfected with GFP protein and the above experimental control groups with a concentration of 200nM were mixed in DMEM medium and incubated in a 37°C, 5% CO2 incubator for 1 hour, then the virus cell culture supernatant was removed, the cells were washed with PBS to remove excess virus and neutralizing aptamers, 500ul of new medium was added again, and the cells were placed in a 37°C, 5% CO2 incubator for 6 hours and then washed with PBS 3 times, and new medium was added again and cultured continuously for 48 hours. The fluorescence intensity signal of GFP-positive cells was detected by flow cytometry. Statistical tests between each treatment group were performed by Graphpad 8.0 software. The DMEM medium includes 90% high-glucose DMEM and 10% FBS.

[0074] Figure 2 The AB results all show that when the specific aptamer (Apt-Mix) of the present invention and the tFNA without modified Aptamer act alone on the new coronavirus SARS-COV-2, it has a good effect on preventing the virus from binding to the ACE2 receptor on the cell surface and infecting cells, thereby achieving a certain degree of antiviral infection effect; and when the specific aptamer is modified on the tetrahedral nucleic acid framework to synthesize the framework nucleic acid aptamer (A-tFNA), compared with the single aptamer and tFNA, the A-tFNA effectively achieves the targeted capture of the new coronavirus SARS-CoV-2 spike protein, thereby It obviously hinders the binding of the virus surface spike protein with the cell ACE2 receptor, significantly improving the anti-viral infection effect; and, experimental research has found that the spatial distance and orderly arrangement of the aptamer combination have an important influence on the neutralization of viral infection. The present invention forms a tetrahedral nucleic acid framework by adjusting the length of the framework sequence to accurately control the spatial distance between the aptamer combinations modified thereon, so that the final framework nucleic acid aptamers (A-t13, A-t17, A-t21) have excellent anti-viral infection effects, and the effect is significantly better than A-t26, among which the framework nucleic acid aptamer A-t17 has the best anti-infection effect.

[0075] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A framework nucleic acid aptamer, characterized in that: The framework nucleic acid aptamer comprises a framework sequence, a linker sequence and an aptamer sequence; the aptamer sequence is connected to the framework sequence through the linker sequence, and then assembled to form a tetrahedral framework nucleic acid aptamer according to the principle of base complementary pairing; The framework sequence includes four DNA chains, and the nucleotide sequences of the four DNA chains are shown in at least one group of (1)-(3): (1)ssDNA A13: 5'-ACACTACGTCAGAACAGCTTGCATCACTGGTCACC AGAGTA-3', ssDNA B13: 5'-ACGAGCGAGTTGATGTGATGCAAGCTGAATGCGAGGGT CCT-3', ssDNA C13: 5'-TCAACTCGCTCGTAACTACACTGTGCAATACTCTGGTG ACC-3', ssDNA D13: 5'-TCTGACGTAGTGTATGCACAGTGTAGTAAGGACCCTCG CAT-3'; (2)ssDNA A17: 5'-ACATTCCTAAGTCTGAAACATTACAGCTTGCTACA CGAGAAGAGCCGCCATAGTA-3', ssDNA B17: 5'-TATCACCAGGCAGTTGACAGTGTAGCAAGCTGTAATAGATGCGAGGGTCCAATAC-3', ssDNA C17: 5'-TCAACTGCCTGGTGATAAAACGACACTACGTGGGAAT CTACTATGGCGGCTCTTC-3', ssDNA D17: 5'-TTCAGACTTAGGAATGTGCTTCCCACGTAGTGTCGTT TGTATTGGACCCTCGCAT-3'; (3)ssDNA A21: 5'-ATTTATCACCCGCCATAGTAGACGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAA-3', ssDNA B21: 5'-ACATGCGAGGGTCCAATACCGACGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTCG-3', ssDNA C21: 5'-ACTACTATGGCGGGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCC-3', ssDNA D21: 5'-ACGGTATTGGACCCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCG-3'; The nucleotide sequence of the aptamer sequence is shown in at least one of (S1)-(S3): (S1)5'-CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGC GTTAATGGACA-3'; (S2)5'-ATCCAGAGTGACGCAGCATTTCATCGGGTCCAAAAGGGGCTGCTCGGGATTGCGGATATGGACACGT-3'; (S3)5'-CGCAGCACCCAAGAACAAGGACTGCTTAGGATTGCGA TAGGTTCGG-3'.

2. The framework nucleic acid aptamer according to claim 1, characterized in that: The nucleotide sequences of the four DNA chains of the framework sequence are as follows: ssDNA A17: 5'-ACATTCCTAAGTCTGAAACATTACAGCTTGCTACA CGAGAAGAGCCGCCATAGTA-3', ssDNA B17: 5'-TATCACCAGGCAGTTGACAGTGTAGCAAGCTGTAATAGATGCGAGGGTCCAATAC-3', ssDNA C17: 5'-TCAACTGCCTGGTGATAAAACGACACTACGTGGGAAT CTACTATGGCGGCTCTTC-3', ssDNA D17: 5'-TTCAGACTTAGGAATGTGCTTCCCACGTAGTGTCGTT TGTATTGGACCCTCGCAT-3'.

3. The framework nucleic acid aptamer according to claim 1, characterized in that: The nucleotide sequence of the aptamer sequence includes three nucleotide sequences shown in (S1)-(S3): (S1)5'-CAGCACCGACCTTGTGCTTTGGGAGTGCTGGTCCAAGGGC GTTAATGGACA-3'; (S2)5'-ATCCAGAGTGACGCAGCATTTCATCGGGTCCAAAAGGGGCTGCTCGGGATTGCGGATATGGACACGT-3'; (S3)5'-CGCAGCACCCAAGAACAAGGACTGCTTAGGATTGCGA TAGGTTCGG-3'.

4. The framework nucleic acid aptamer according to claim 1, characterized in that: The aptamer sequence targets the RBD domain of the SARS-CoV-2 spike protein.

5. The framework nucleic acid aptamer according to claim 1, characterized in that: The nucleotide sequence of the linker sequence includes tttttttttt.

6. The framework nucleic acid aptamer according to claim 1, characterized in that: The effective concentration of the framework nucleic acid aptamer is 200-1000 nM.

7. The method for preparing a framework nucleic acid aptamer according to any one of claims 1 to 6, characterized in that: The following steps are involved: The aptamer sequence is connected to the structural end of the framework sequence DNA chain through the linker sequence, and then the four DNA chains of the framework sequence are mixed with 10×TM buffer and water, and then a PCR reaction is performed to obtain the framework nucleic acid aptamer; The four DNA chains of the framework sequence have the same volume usage; the usage ratio of the framework sequence, 10×TM buffer and water is 4 μmoL:10 μL:50 μL.

8. The preparation method according to claim 7, characterized in that: The TM buffer comprises the following components: 200mmol / L Tris-HCl and 500mmol / L MgCl2 at pH 8.

0.

9. The preparation method according to claim 7, characterized in that: The conditions of the PCR reaction are: preheating at 95°C for 3 minutes, denaturation at 95°C for 10 minutes, annealing to 4°C for 20 minutes.

10. Use of the framework nucleic acid aptamer according to any one of claims 1 to 6 in the preparation of a drug for preventing or treating pneumonia caused by SARS-COV-2 virus infection.

Citation Information

Cited By

  • Method for anchoring and sorting protoplast by using DNA tetrahedral framework nucleic acid specificity

    CN121136903A

  • A method for sorting protoplasts using DNA tetrahedral framework nucleic acid specific anchoring

    CN121136903B